Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 196

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 196
---
 the Registrant and Michael Carulli.
     
    10-K
     
    001-39539
     
    10.22
     
    February 29, 2024

    10.17+
     
    Consulting Agreement, dated February 13, 2024, by and between the Registrant and Charles Baum, MD., Ph.D.
     
    10-K
     
    001-39539
     
    10.23
     
    February 29, 2024

    10.18+
     
    Amended and Restated Change in Control and Severance Policy Participation Agreement, dated January 5, 2024, by and between the Registrant and Michael Carulli.
     
    10-K
     
    001-39539
     
    10.24
     
    February 29, 2024

    19.1*
     
    Insider Trading Policy.

    21.1
     
    List of Subsidiaries.
     
    10-K
     
    001-39539
     
    21.1
     
    March 1, 2022

    23.1*
     
    Consent of Independent Registered Public Accounting Firm.

    24.1*
     
    Power of Attorney (contained in the signature page to this Annual Report on Form 10-K).

    31.1*
     
    Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

    31.2*
     
    Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

    32.1*#
     
    Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

    32.2*#
     
    Certification of Principal Financial Officer Pursuant to 18 U.S.C.